Trials / Terminated
TerminatedNCT04099277
A Study of LY3435151 in Participants With Solid Tumors
A Phase 1a/1b Study of LY3435151 Administered to Patients With Advanced Solid Tumors
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 2 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The reason for this study is to see if the study drug LY3435151 is safe in participants with advanced solid tumors.
Conditions
- Solid Tumor
- Triple-negative Breast Cancer
- Gastric Adenocarcinoma
- Head and Neck Squamous Cell Carcinoma
- Cervical Carcinoma
- High Grade Serous Ovarian Carcinoma
- Hepatocellular Carcinoma
- Undifferentiated Pleomorphic Sarcoma
- Leiomyosarcoma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3435151 | Administered IV |
| DRUG | Pembrolizumab | Administered IV |
Timeline
- Start date
- 2019-10-28
- Primary completion
- 2020-03-05
- Completion
- 2020-03-05
- First posted
- 2019-09-23
- Last updated
- 2021-08-31
- Results posted
- 2021-08-31
Locations
2 sites across 2 countries: United States, Japan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04099277. Inclusion in this directory is not an endorsement.